Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed or Refractory CD19+ B-cell Lymphoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableTemporarily pausedNCT03229876
What this trial is testing

Safety and Efficacy Evaluation of CD19-UCART

Who this might be right for
Acute Lymphoblastic Leukemia (ALL)Non Hodgkin Lymphoma (NHL)
Bioray Laboratories 20
Early research (Phase 1)Active Not RecruitingNCT02879695
What this trial is testing

Blinatumomab and Nivolumab With or Without Ipilimumab in Treating Patients With Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

Who this might be right for
Recurrent B Acute Lymphoblastic LeukemiaRecurrent Mixed Phenotype Acute LeukemiaRefractory B Acute Lymphoblastic Leukemia+1 more
National Cancer Institute (NCI) 28
Early research (Phase 1)Active Not RecruitingNCT05574114
What this trial is testing

Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma

Who this might be right for
Non-Hodgkin LymphomaNon-Hodgkin's Lymphoma, RelapsedNon-Hodgkin's Lymphoma Refractory
Memorial Sloan Kettering Cancer Center 20
Early research (Phase 1)UnknownNCT02842138
What this trial is testing

Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell Lymphoma

Who this might be right for
B-cell Lymphoma
Peking University 25
Very early researchLooking for participantsNCT06446128
What this trial is testing

A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)

Who this might be right for
Non-Hodgkin Lymphoma, B-cell
Shanghai Cell Therapy Group Co.,Ltd 20
Large-scale testing (Phase 3)WithdrawnNCT06205290
What this trial is testing

Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Who this might be right for
Leukemia, Lymphocytic, Chronic, B-Cell
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Testing effectiveness (Phase 2)Study completedNCT01466153
What this trial is testing

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)
MedImmune LLC 183
Testing effectiveness (Phase 2)Looking for participantsNCT04186520
What this trial is testing

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

Who this might be right for
Non Hodgkin Lymphoma (NHL)Mantle Cell Lymphoma (MCL)Chronic Lymphocytic Leukemia (CLL)+5 more
Medical College of Wisconsin 100
Early research (Phase 1)Looking for participantsNCT05741359
What this trial is testing

The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma

Who this might be right for
Non-hodgkin Lymphoma,B Cell
Bioray Laboratories 18
Testing effectiveness (Phase 2)Looking for participantsNCT03676504
What this trial is testing

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

Who this might be right for
Acute Lymphoblastic Leukemia, AdultAcute Lymphoblastic Leukemia, PediatricChronic Lymphocytic Leukemia+3 more
University Hospital Heidelberg 68
Early research (Phase 1)UnknownNCT04684472
What this trial is testing

Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies

Who this might be right for
Refractory B-Cell Non-Hodgkin LymphomaRefractory Leukemia
Liqun Zou 18
Testing effectiveness (Phase 2)UnknownNCT04626908
What this trial is testing

Clinical Study of Targeting CD19 and CD22 Chimeric Antigen Receptor T Lymphocytes in the Treatment of Recurrent or Refractory B Cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed and RefractoryLymphoid Hematological Malignancies
He Huang 18
Very early researchLooking for participantsNCT06346912
What this trial is testing

CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL

Who this might be right for
Acute Lymphoblastic Leukemia,B-CellNon-hodgkin Lymphoma,B Cell
Zhejiang University 20
Early research (Phase 1)Study completedNCT04696432
What this trial is testing

C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkin's B-cell Lymphoma
Tianjin Medical University Cancer Institute and Hospital 7
Testing effectiveness (Phase 2)Looking for participantsNCT06880913
What this trial is testing

Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL

Who this might be right for
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Peking University People's Hospital 50
Testing effectiveness (Phase 2)Study completedNCT03994913
What this trial is testing

Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma

Who this might be right for
Refractory B-Cell Non-Hodgkin LymphomaRelapsed B-cell Non-Hodgkin Lymphoma
CARsgen Therapeutics Co., Ltd. 20
Not applicableApproved For MarketingNCT04300803
What this trial is testing

Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL

Who this might be right for
DLBCL
MorphoSys AG
Testing effectiveness (Phase 2)Study completedNCT01865617
What this trial is testing

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

Who this might be right for
CD19-Positive Neoplastic Cells PresentRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Chronic Lymphocytic Leukemia+10 more
Fred Hutchinson Cancer Center 204
Early research (Phase 1)Looking for participantsNCT06559189
What this trial is testing

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
University of Colorado, Denver 53
Early research (Phase 1)Ended earlyNCT03593109
What this trial is testing

A Single-center Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LCAR-L10D Cell Formulations Targeting CD19 and CD22 in Patients With CD19- and/or CD22-Positive Relapsed/Refractory B-cell Lymphoma

Who this might be right for
Lymphoma, B-Cell
Second Affiliated Hospital of Xi'an Jiaotong University 1
Next Page